{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:36:45Z","timestamp":1786649805193,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bleomycin-induced pulmonary (BIP) toxicity is a notorious entity and cropped up in roughly 10% of cases. The aim of the study is to evaluate BIP at our tertiary care cancer center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This is a retrospective, analytical study conducted at a tertiary care center from January 1998 to December 2012. Records of all the patients who were offered bleomycin chemotherapy as an integral part of adriamycin, bleomycin, vinblastine, and dacarbazine or bleomycin, etoposide, and cisplatin regimen in Hodgkin disease (HD) or germ cell tumor (GCT) were studied for the study inclusion criteria. Twenty-two patients treated with bleomycin who had respiratory symptoms and\/or abnormal high-resolution computed tomography (HRCT) findings, suggestive of bleomycin-induced lung injury were included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and Statistical Analysis:<\/jats:title>\n                    <jats:p>A total of 22 patients met the inclusion criteria for the study cohort. Of 22 patients, 8 were of HD and 14 were of GCT (nonseminomatous GCT [NSGCT] = 10 and seminomatous GCT = 4). Of 22 patients, 14 had symptoms of nonproductive cough, dyspnea and showed HRCT findings of ground glass opacities, diffuse alveolar damage, extensive reticular markings, traction bronchiectasis, and\/or nodular densities. Two patients had fever and pleuritic pain. Eight patients were asymptomatic. Symptomatic patients were treated with prednisone at the dose of 0.75\u20131 mg\/kg 4\u20138 weeks then gradually tapered. Four patients required noninvasive ventilatory support and managed with oxygen, nebulization, and antibiotics. Two patients required mechanical ventilatory support (HD = 1 and NSGCT = 1) and developed multiorgan failure subsequently succumbed to death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BIP is noteworthy lung toxicity as subsequent mortality ranges from 10% to 20% and shrinks survival rate in patients with highly curable malignant conditions. Physicians should be vigilant concerning this impending side effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.204887","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T06:04:42Z","timestamp":1492668282000},"page":"466-470","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary toxicity following bleomycin use: A single-center experience"],"prefix":"10.4103","volume":"13","author":[{"given":"Irappa","family":"Madabhavi","sequence":"first","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurang","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1378\/chest.120.2.617","article-title":"Bleomycin-induced pneumonitis","volume":"120","author":"Sleijfer","year":"2001","journal-title":"Chest"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"11636","DOI":"10.1016\/S0021-9258(19)68452-8","article-title":"Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA","volume":"256","author":"Burger","year":"1981","journal-title":"J Biol Chem"},{"key":"R3-20260109","article-title":"Bleomycin-induced lung injury","volume":"9","author":"Reinert","year":"2013","journal-title":"J Cancer Res"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrc1547","article-title":"Bleomycins: Towards better therapeutics","volume":"5","author":"Chen","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/bjc.1998.628","article-title":"Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95: A review of patients with germ cell tumours","volume":"78","author":"Simpson","year":"1998","journal-title":"Br J Cancer"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0272-5231(21)00669-9","article-title":"Possible mechanisms of bleomycin-induced fibrosis","volume":"11","author":"Chandler","year":"1990","journal-title":"Clin Chest Med"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thx.42.7.551","article-title":"Bronchoalveolar lavage cell populations in bleomycin lung toxicity","volume":"42","author":"White","year":"1987","journal-title":"Thorax"},{"key":"R8-20260109","first-page":"321","article-title":"Drug-induced pulmonary disease. Part 1: Cytotoxic drugs","volume":"133","author":"Cooper","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","article-title":"Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group","volume":"15","author":"de Wit","year":"1997","journal-title":"J Clin Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1378\/chest.101.1.97","article-title":"Bleomycin-induced pulmonary function abnormalities","volume":"101","author":"Wolkowicz","year":"1992","journal-title":"Chest"},{"issue":"2 Suppl 5","key":"R11-20260109","first-page":"64","article-title":"Bleomycin pulmonary toxicity: Current status and future directions","volume":"19","author":"Comis","year":"1992","journal-title":"Semin Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/1097-0142(19890815)64:4<806::AID-CNCR2820640407>3.0.CO;2-X","article-title":"Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma","volume":"64","author":"Santrach","year":"1989","journal-title":"Cancer"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1378\/chest.07-0223","article-title":"Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients","volume":"132","author":"Boll\u00e9e","year":"2007","journal-title":"Chest"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00002018-200528020-00002","article-title":"Interstitial lung disease in lung cancer: Separating disease progression from treatment effects","volume":"28","author":"Danson","year":"2005","journal-title":"Drug Saf"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1378\/chest.111.3.657","article-title":"Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor","volume":"111","author":"Saxman","year":"1997","journal-title":"Chest"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.1989.7.3.387","article-title":"Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol","volume":"7","author":"Einhorn","year":"1989","journal-title":"J Clin Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mdg076","article-title":"Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up","volume":"14","author":"Canellos","year":"2003","journal-title":"Ann Oncol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.86.5.723","article-title":"Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids","volume":"86","author":"White","year":"1984","journal-title":"Chest"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4997\/JRCPE.2010.306","article-title":"Toxicities associated with bleomycin","volume":"40","author":"Fyfe","year":"2010","journal-title":"J R Coll Physicians Edinb"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1200\/JCO.2011.35.6733","article-title":"Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: Hope for severe chemotherapy-induced toxicity?","volume":"29","author":"Carnevale-Schianca","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201713030-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:37Z","timestamp":1786647517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201713030-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.204887","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}